Since SIRPα blockade reverts MDSCs to a less suppressive phenotype and promotes phagocytosis, antigen processing, and presentation of tumor-derived material (Figures 7C–7F), we then tested the impact of SIRPα blockade, and its affects, on B16.F10 tumor development in vivo. This evidence concerns the gene SIRPA and neoplasm.